ZOLL Medical Corporation

ZOLL Medical Corporation

ZOLL was founded in 1980 and is named after Dr. Paul Zoll, a cardiologist known as 'The Father of Modern Cardiac Therapy' (per company). The firm operates as a wholly owned subsidiary of Asahi Kasei, a Japanese conglomerate with over 50,000 employees worldwide. Its wealth origin traces to Asahi Kasei, which entered healthcare through acquisitions including ZOLL. The company's product portfolio spans defibrillation and cardiac monitoring, circulation enhancement with CPR feedback, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment. ZOLL sells these devices to hospitals, emergency medical services, military organizations, and lay rescuers. Confirmed offerings include the LifeVest wearable cardioverter defibrillator, the Zenix monitor-defibrillator (approved under EU MDR), and the remedē System for central sleep apnea. ZOLL's geographic footprint covers North America, Europe, and other regions. ZOLL employs approximately 10,000 people globally (Asahi Kasei's healthcare segment). The company recently received MDR approval for its Zenix monitor-defibrillator in the European Union (per company, press release). Its parent Asahi Kasei also operates homes and materials businesses. ZOLL's structural differentiator is its position as a standalone operating subsidiary within a larger industrial conglomerate — not a family office. Its capital is deployed into R&D and manufacturing for medical devices, not external investments. Succession and governance follow Asahi Kasei's corporate structure.